Article Figures & Data
Figures
- FIGURE 1.
Activity ratios of hot cylinders to background, with cylinders of 8-, 12-, 16-, and 25-mm diameter for 64Cu and 60Cu (without and with cascade coincidence subtraction [CS]). Ratios of hot cylinder to uniform area in A are averages within cylinder and in B are peak values. Values were normalized to expected ratio of 9.87 to be equal to 1.
- FIGURE 2.
Correlation of 60Cu-ATSM uptake (without and with cascade subtraction [CS]) and 64Cu-ATSM uptake in 10 patients with cervical cancer. Results are expressed as T/M ratios. Good correlation between uptakes of these 2 radiotracers was found. This analysis was performed to demonstrate that similar T/M ratios can be obtained with both nuclides and that applying 60Cu cascade coincidence correction improves comparability of measured T/M ratios. Linear regressions were determined by setting y-intercept to zero and slope derived from least-square minimization.
- FIGURE 3.
(A) Transaxial CT (top left) and 18F-FDG PET (top right) images of pelvis show intense 18F-FDG uptake within known cervical tumor at site of cervical mass seen on CT. Transaxial 30- to 60-min summed images of 60Cu-ATSM PET (bottom left) and 64Cu-ATSM PET (bottom right) of pelvis at same level demonstrate mildly increased uptake within known primary cervical tumor. There are similar patterns of 60Cu-ATSM and 64Cu-ATSM uptake within tumor. (B) Transaxial coregistered 18F-FDG PET/CT (top left) and 18F-FDG PET (top right) images of pelvis show intense 18F-FDG uptake within known cervical tumor at site of cervical mass seen on CT. Transaxial 30- to 60-min summed images of 60Cu-ATSM PET (bottom left) and 64Cu-ATSM PET (bottom right) of pelvis at same level demonstrate markedly increased uptake within known primary cervical tumor. There are similar patterns of 60Cu-ATSM and 64Cu-ATSM uptake within tumor.
Tables
Age (y) First scan Days between copper-ATSM scans 60Cu activity injected 64Cu activity injected T/M ratio Patient no. Stage MBq mCi MBq mCi 60Cu 60Cu(CS) 64Cu 1 65 IIIA 60Cu 7 518 14.0 821 22.2 3.5 6.0 4.4 2 77 IIB 64Cu 9 352 9.5 918 24.8 5.7 6.3 7.2 3 33 IB1 64Cu 7 529 14.3 855 23.1 5.3 6.3 5.9 4 59 IIIB 64Cu 6 629 17.0 925 25.0 6.2 7.3 7.4 5 79 IIIB 60Cu 1 714 19.3 925 25.0 3.6 4.7 4.9 6 46 IIIB 64Cu 9 740 20.0 925 25.0 7.2 8.8 9.2 7 43 IIIB 60Cu 5 592 16.0 907 24.5 8.1 10.2 10.4 8 60 IIB 64Cu 7 204 5.5 925 25.0 7.9 9.8 8.4 9 45 IB2 64Cu 6 285 7.7 910 24.6 6.6 7.7 8.6 10 55 IIB 60Cu 1 222 6.0 895 24.2 5.0 5.9 7.1 Mean ± SD 5.9 ± 1.6 7.3 ± 1.8 7.3 ± 1.9
Jump to section
Related Articles
Cited By...
- The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis
- A Comparison of the Imaging Characteristics and Microregional Distribution of 4 Hypoxia PET Tracers
- Cardiac Hypoxia Imaging: Second-Generation Analogues of 64Cu-ATSM
- Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics
- VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study
- Application of 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET Imaging to Predict Highly Malignant Tumor Grades and Hypoxia-Inducible Factor-1{alpha} Expression in Patients with Glioma
- Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
- Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model
- Molecular Imaging of Hypoxia
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET